Skip to content

Lung Cancer Screening in Population Who Had Never Smoked

Lung Cancer Screening in Population Who Had Never Smoked and the Validation of Lung Cancer Risk Prediction Model

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07383454
Enrollment
2500
Registered
2026-02-03
Start date
2026-02-01
Completion date
2034-12-01
Last updated
2026-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Cancer (Diagnosis), Non-Small Cell Lung Cancer, Screening Strategy, Small Cell Carcinoma of Lung

Keywords

Low dose computed tomography (LDCT), Lung cancer in individuals who had never smoked (LCINS), Lung cancer risk prediction model (LCRPM), Lung cancer, Non-small cell lung cancer (NSCLC)

Brief summary

Study design: prospective, single arm. Objectives: survey lung cancer detection rate of low-dose computed tomography (LDCT) screening in individuals who had never smoked. Participants will undergo questionnaires, and collecting specimens including blood, urine, and medical informations including results of pulmonary function tests, and LDCT screening upon inclusion. The participants will be followed up according to current standards of clinical practice.

Detailed description

Lung cancer remains the leading cause of cancer-related mortality worldwide, with a particularly high incidence and mortality rate in Taiwan. Notably, over half of lung cancer cases in Taiwan occur among individuals who have never smoked, a pattern distinct from Western populations. In response to this unique epidemiological profile, this project aims to promote community-based lung cancer screening among never-smokers and to validate the FORMOSA lung cancer risk prediction model, which integrates demographic, environmental, genetic, and clinical factors. This prospective, single-arm, open-label study will recruit approximately 2,500 participants aged 40 to 80 years with no history of smoking, through hospital and community outreach. Eligible participants will provide informed consent and undergo comprehensive assessments, including questionnaires on lifestyle and environmental exposures, low-dose computed tomography (LDCT), chest X-ray, pulmonary function tests, and collection of blood and urine samples. LDCT results will be interpreted according to the modified ACR Lung-RADS v1.1 criteria. Biological specimens will be used for biomarker, heavy metal, genetic, and proteomic analyses. Participants with abnormal findings will be followed according to standard clinical protocols, and tissue samples from invasive procedures will be retained for further molecular studies. The primary outcomes include the lung cancer detection rate among never-smoked participants and the validation metrics (sensitivity, specificity, positive and negative predictive values) of the FORMOSA lung cancer risk prediction model. Statistical analyses will employ descriptive statistics, Kaplan-Meier survival analysis, log-rank tests, Cox proportional hazards models, and group comparisons using ANOVA, Kruskal-Wallis, chi-square, Fisher's exact tests, and logistic-regression. Preliminary data suggest that the FORMOSA model can identify high-risk individuals with a lung cancer detection rate of 2.8-3.3%, significantly higher than the general population rate of 0.78%. This project is expected to enhance early detection of lung cancer in never-smokers, improve public awareness, and establish a robust epidemiological database for Taiwan. The validation of the FORMOSA model will provide a scientific basis for refining screening strategies and inform future public health policies targeting high-risk, non-smoking populations. The study is conducted with strict adherence to ethical standards, ensuring participant rights and data security. Funding is provided by the Ministry of Health and Welfare's "Healthy Taiwan Deep Cultivation Plan." In summary, this research addresses a critical gap in lung cancer prevention by focusing on never-smokers, leveraging a comprehensive risk prediction model, and implementing a community-based screening approach. The anticipated outcomes will contribute significantly to reducing late-stage lung cancer diagnoses and mortality, and serve as a reference for future health policy development in Taiwan and similar populations.

Interventions

Low dose computed tomography for lung cancer screening

Sponsors

Chung Shan Medical University
Lead SponsorOTHER
Ministry of Health and Welfare, Taiwan
CollaboratorOTHER_GOV

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SCREENING
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
40 Years to 80 Years
Healthy volunteers
Yes

Inclusion criteria

1. Individuals with no history of smoking. 2. Aged 40 to 80 years. 3. Willing to provide written informed consent and complete questionnaire assessments. 4. After undergoing examinations, willing to provide relevant biological information, including but not limited to: blood samples, urine samples, pulmonary function test results, imaging data, and tissue specimens obtained from invasive biopsies or surgical procedures (if applicable).

Exclusion criteria

1. History of lung cancer, or a diagnosis of any malignancy other than skin cancer or cervical carcinoma in situ within the past five years. 2. Undergoing chest computed tomography (CT) scans within the past 18 months. 3. Unexplained hemoptysis within the past one month. 4. Unexplained weight loss exceeding 6 kilograms within the past one year. 5. Pregnancy.

Design outcomes

Primary

MeasureTime frameDescription
Lung cancer detection rate8 years of follow-upThe rate of lung cancer diagnosis during follow up periord.

Secondary

MeasureTime frameDescription
AUROC of FORMOSA Lung Cancer Risk Prediction Model8 yearsAssess the sensitivity, specificity, positive predicting value, negative predicting value, and ROC analysis of FORMOSA Lung Cancer Risk Prediction Model

Contacts

CONTACTGee-Chen Chang, MD, PhD.
geechen@gmail.com886-4-24739595
CONTACTLung-Ying Huang, Mrs.
cshe1365@csh.org.tw886-4-24739595

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026